



Express Mail No.: **EV 473 970 735 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schneider *et al.*

Confirmation No.: 1583

Application No.: 09/305,084

Group Art Unit: 1643

Filed: May 4, 1999

Office Action: Canella, Karen A.

For: CANCER TREATMENT WITH
ENDOTHELIN RECEPTOR ANTAGONISTS

Attorney Docket No.: 5914-080-999
Cam No.: 007402-999079

RESPONSE UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed October 20, 2006, please enter the following remarks made below in connection with the above-identified application. Submitted herewith are:

1. a Petition for Extension of Time (in duplicate) for three months, from January 20, 2007, up to and including April 20, 2007;
2. a copy of the Declaration of Dr. Robert J. Schneider and Dr. Sumayah Jamal under 37 C.F.R. § 1.131 filed July 24, 2006;
3. executed Supplemental Declaration of Dr. Robert J. Schneider and Dr. Sumayah Jamal under 37 C.F.R. § 1.131 (in two counterparts); and
4. a Supplemental Information Disclosure Statement, including a List of References Cited by Applicant and a copy of Reference C10.

It is estimated that no additional fee is required for filing this Amendment. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 503013.

Listing of Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 5 of this paper.